133 related articles for article (PubMed ID: 1543544)
1. Murine p53 intron sequences 5-8 and their use in polymerase chain reaction/direct sequencing analysis of p53 mutations in CD-1 mouse liver and lung tumors.
Goodrow TL; Storer RD; Leander KR; Prahalada SR; van Zwieten MJ; Bradley MO
Mol Carcinog; 1992; 5(1):9-15. PubMed ID: 1543544
[TBL] [Abstract][Full Text] [Related]
2. Dose-related changes in the profile of ras mutations in chemically induced CD-1 mouse liver tumors.
Manam S; Shinder GA; Joslyn DJ; Kraynak AR; Hammermeister CL; Leander KR; Ledwith BJ; Prahalada S; van Zwieten MJ; Nichols WW
Carcinogenesis; 1995 May; 16(5):1113-9. PubMed ID: 7767973
[TBL] [Abstract][Full Text] [Related]
3. Correlation of immunohistochemical staining and mutations of p53 in human hepatocellular carcinoma.
Hsia CC; Nakashima Y; Thorgeirsson SS; Harris CC; Minemura M; Momosaki S; Wang NJ; Tabor E
Oncol Rep; 2000; 7(2):353-6. PubMed ID: 10671685
[TBL] [Abstract][Full Text] [Related]
4. Activation of the Ha-, Ki-, and N-ras genes in chemically induced liver tumors from CD-1 mice.
Manam S; Storer RD; Prahalada S; Leander KR; Kraynak AR; Ledwith BJ; van Zwieten MJ; Bradley MO; Nichols WW
Cancer Res; 1992 Jun; 52(12):3347-52. PubMed ID: 1596892
[TBL] [Abstract][Full Text] [Related]
5. Ras proto-oncogene activation in liver and lung tumors from B6C3F1 mice exposed chronically to methylene chloride.
Devereux TR; Foley JF; Maronpot RR; Kari F; Anderson MW
Carcinogenesis; 1993 May; 14(5):795-801. PubMed ID: 8504471
[TBL] [Abstract][Full Text] [Related]
6. Screening for p53 mutations in C3H/He mouse liver tumors derived spontaneously or induced with diethylnitrosamine or phenobarbitone.
Rumsby PC; Davies MJ; Evans JG
Mol Carcinog; 1994 Feb; 9(2):71-5. PubMed ID: 8142011
[TBL] [Abstract][Full Text] [Related]
7. p53 gene in hepatocellular carcinomas from Australia.
Vesey DA; Hayward NK; Cooksley WG
Cancer Detect Prev; 1994; 18(2):123-30. PubMed ID: 8025894
[TBL] [Abstract][Full Text] [Related]
8. Absence of p53 mutations and various frequencies of Ki-ras exon 1 mutations in rat hepatic tumors induced by different carcinogens.
Tokusashi Y; Fukuda I; Ogawa K
Mol Carcinog; 1994 May; 10(1):45-51. PubMed ID: 8185829
[TBL] [Abstract][Full Text] [Related]
9. Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice.
Hegi ME; Söderkvist P; Foley JF; Schoonhoven R; Swenberg JA; Kari F; Maronpot R; Anderson MW; Wiseman RW
Carcinogenesis; 1993 May; 14(5):803-10. PubMed ID: 8504472
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B and alterations of the p53 tumor suppressor gene in hepatocellular carcinoma.
Goldblum JR; Bartos RE; Carr KA; Frank TS
Am J Surg Pathol; 1993 Dec; 17(12):1244-51. PubMed ID: 8238731
[TBL] [Abstract][Full Text] [Related]
11. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent ras mutation spectra in N-nitrosodiethylamine induced mouse liver tumors and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced mouse lung tumors.
Chen B; Liu L; Castonguay A; Maronpot RR; Anderson MW; You M
Carcinogenesis; 1993 Aug; 14(8):1603-8. PubMed ID: 8353844
[TBL] [Abstract][Full Text] [Related]
13. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
14. p53 abnormalities in hepatocellular carcinoma from United States patients: analysis of all 11 exons.
Kazachkov Y; Khaoustov V; Yoffe B; Solomon H; Klintmalm GB; Tabor E
Carcinogenesis; 1996 Oct; 17(10):2207-12. PubMed ID: 8895490
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the tumor suppressor gene p53 in human liver cancer induced by alpha-particles.
Andersson M; Jönsson M; Nielsen LL; Vyberg M; Visfeldt J; Storm HH; Wallin H
Cancer Epidemiol Biomarkers Prev; 1995; 4(7):765-70. PubMed ID: 8672994
[TBL] [Abstract][Full Text] [Related]
16. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas.
Murakami Y; Hayashi K; Hirohashi S; Sekiya T
Cancer Res; 1991 Oct; 51(20):5520-5. PubMed ID: 1655254
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain.
Challen C; Lunec J; Warren W; Collier J; Bassendine MF
Hepatology; 1992 Dec; 16(6):1362-6. PubMed ID: 1332921
[TBL] [Abstract][Full Text] [Related]
18. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.
Rall CJ; Yan YX; Graeme-Cook F; Beauchamp R; Yandell DW; Povoski SP; Rustgi AK
Pancreas; 1996 Jan; 12(1):10-7. PubMed ID: 8927612
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.
Chiba I; Takahashi T; Nau MM; D'Amico D; Curiel DT; Mitsudomi T; Buchhagen DL; Carbone D; Piantadosi S; Koga H
Oncogene; 1990 Oct; 5(10):1603-10. PubMed ID: 1979160
[TBL] [Abstract][Full Text] [Related]
20. p53 mutations in human lung tumors.
Miller CW; Simon K; Aslo A; Kok K; Yokota J; Buys CH; Terada M; Koeffler HP
Cancer Res; 1992 Apr; 52(7):1695-8. PubMed ID: 1312896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
